
Opinion|Videos|April 4, 2025
Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
Panelists discuss how clinicians should interpret Clinical Dementia Rating-Sum of Boxes (CDR-SB) score changes by correlating numerical shifts with meaningful real-world outcomes, considering both the statistical significance and clinical meaningfulness of changes, recognizing that even modest improvements may represent significant functional preservation for patients, and contextualizing these changes within individual patient circumstances, disease trajectory, and impact on quality of life.
Advertisement
Video content above is prompted by the following:
- How should clinicians interpret changes in CDR-SB scores in terms of real-world functional and cognitive benefits for patients?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
Boston Panel Confronts Access and Coordination Gaps in Obesity Care
5






